Cochlear implant (CI) surgeons are faced with the increasingly difficult task of choosing the “right” device despite a growing number of choices and conflicting evidence regarding the relative importance of various anatomic, surgical, and device-specific factors.
The osseointegrated steady state implant 2 (OSIA2) system was developed to provide hearing through bone conduction while avoiding complications previously reported in children using percutaneous devices.
The multicenter, double-blind, randomized, placebo-controlled trial protocol was shown to be feasible and demonstrated the need for blinded randomized controlled trials to objectively measure the efficacy of balloon Eustachian tuboplasty.
People with bilateral cochlear implantation have diminished perception of musical attributes, which limits their emotional response when listening
Electrocochleography (ECoG) has historically been used for measuring hearing thresholds and identifying endolymphatic hydrops in Ménière’s disease. More recently, ECoG application has expanded to monitor electrical potentials during cochlear implantation as an indirect measure of cochlear trauma.
Although functional outcome expectations are similar between candidates who elect to receive or forgo cochlear implants, the latter have higher baseline CI-specific quality of life abilities.
Findings suggest that cancer survivors have a significantly higher prevalence of both audiometry-confirmed and self-reported hearing loss than the general population.
Randomized controlled trials with standardized hyperbaric oxygen therapy treatment protocols and attention to social determinants of health and other confounders are desperately needed to establish efficacy.
A potential solution for lack of cadaveric temoral bone has been the use of virtual or 3D-printed temporal bones to simulate the drilling exercise and provide specimens to teach anatomy and procedures.
This two-stage surgical auricle reconstruction is a versatile, reliable, and effective congenital microtia treatment.